alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

32,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 26–50 of 116 studies with an author at University of California, San Francisco (US) · tagged Risk Factors (page 2 of 5) · 32,180 in the whole library · How the 0–100 score works

Download bibliography of these 116 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 17,651 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Traumatic Brain Injury and Risk of Incident Comorbidities

✓ Peer-reviewed alzhub usefulness score 67 out of 100. JAMA Network Open 2024-12-12

The study consisted of 20 400 patients (9264 female [45.4%]; 1576 Black [7.7%], 3944 Latinx [19.3%], and 10 480 White [51.4%]), including 5100 patients with mTBI (median [IQR] age, 36.0 [25.0-51.0] years), 5100 patients with msTBI (median [IQR age, 35.0 [25.0-52.0] years), and 10 200 matched patients in the control group (median [IQR] age, 36.0 [25.0-51.0] years). 5 key findings →

Design: cohort study Participants: 400 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Statin Initiation and Dementia Incidence in a Large Health Care System From 1997 to 2020: A Target Trial Emulation Study

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Neurology 2025-06-27

Among eligible participants (n = 705,061), 264,294 individuals (37.5% of eligible participants) initiated any statin during 2001-2010 ("initiators"), of whom 249,613 (94.4%) were matched with 255,937 unique noninitiators to create the analytic sample (322,358 unique participants; mean age at baseline = 67.4 years; 55.1% female). 3 key findings →

Design: cohort Participants: 322,358 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Archives of neurology 2012-09-01

Among well-functioning older adults, DM and poor glucose control among those with DM are associated with worse cognitive function and greater decline. 5 key findings →

Design: cohort study Participants: 717 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Visual Impairment, Eye Conditions, and Diagnoses of Neurodegeneration and Dementia

✓ Peer-reviewed alzhub usefulness score 65 out of 100. JAMA Network Open 2024-07-01

In this cohort and MR study of UK Biobank participants, cataracts were associated with increased risk of dementia, especially vascular dementia, and reduced total brain volumes. 5 key findings →

Design: cohort Participants: 304,953 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Anti-inflammatory drugs and risk of Alzheimer's disease: an updated systematic review and meta-analysis

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Journal of Alzheimer's disease : JAD 2015-01-01

Observational studies support the use of NSAIDs for prevention of AD, but RCT do not. 4 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The metabolic syndrome, inflammation, and risk of cognitive decline

✓ Peer-reviewed alzhub usefulness score 65 out of 100. JAMA 2004-11-01

These findings support the hypothesis that the metabolic syndrome contributes to cognitive impairment in elders, but primarily in those with high level of inflammation. 5 key findings →

Participants: 1,616 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Annals of neurology 2011-11-01

Older, healthy women with decreased circadian activity rhythm amplitude and robustness, and delayed rhythms have increased odds of developing dementia and MCI. 3 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Fine-mapping of the human leukocyte antigen locus as a risk factor for Alzheimer disease: A case-control study

✓ Peer-reviewed alzhub usefulness score 64 out of 100. PLoS medicine 2017-03-28

Secondary analysis suggested that this effect may be driven primarily by individuals who are negative for the established AD genetic risk factor, apolipoprotein E (APOE) ɛ4. 5 key findings →

Design: case-control study Participants: 346 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Sleep Duration and White Matter Quality in Middle-Aged Adults

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Sleep 2016-09-01

Study objectives Sleep duration has been associated with risk of dementia and stroke, but few studies have investigated the relationship between sleep duration and brain MRI measures, particularly in middle age. 3 key findings →

Design: prospective cohort Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Sleep architecture and dementia risk in adults: an analysis of 5 cohorts from the Sleep and Dementia Consortium

✓ Peer-reviewed alzhub usefulness score 64 out of 100. SLEEP 2025-05-16

The pooled sample comprised 4657 participants (30% women) aged ≥ 60 years (mean age was 74 years at sleep assessment). 5 key findings →

Design: cohort study Participants: 2,374 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Five-Year Changes in 24-Hour Sleep-Wake Activity and Dementia Risk in Oldest Old Women

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Neurology 2025-03-19

Of 733 participants (mean age 82.5 ± 2.9 years), 164 (22.4%) developed MCI and 93 (12.7%) developed dementia by the follow-up visit. 5 key findings →

Design: longitudinal study Participants: 321 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association Between Birth in a High Stroke Mortality State, Race, and Risk of Dementia

✓ Peer-reviewed alzhub usefulness score 63 out of 100. JAMA neurology 2017-09-01

Overall, birth in an HSMS was associated with a 28% higher risk of dementia (adjusted hazard ratio [aHR], 1.28; 95% CI, 1.13-1.46) adjusted for age, sex, and race. 5 key findings →

Design: cohort study Participants: 7,423 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Traumatic brain injury in later life increases risk for Parkinson disease

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Annals of neurology 2015-03-28

Among patients aged ≥55 years presenting to inpatient/ED settings with trauma, TBI is associated with a 44% increased risk of developing PD over 5 to 7 years that is unlikely to be due to confounding or reverse causation. 4 key findings →

Participants: 52,393 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Nature aging 2021-05-14

The plasma proteomic changes that precede the onset of dementia could yield insights into disease biology and highlight new biomarkers and avenues for intervention. 4 key findings →

Participants: 4,110 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Machine learning reveals distinct neuroanatomical signatures of cardiovascular and metabolic diseases in cognitively unimpaired individuals

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Nature Communications 2025-03-19

Comorbid cardiovascular and metabolic risk factors (CVM) differentially impact brain structure and increase dementia risk, but their specific magnetic resonance imaging signatures (MRI) remain poorly characterized. 1 key finding →

Design: cohort study Participants: 37,096 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Potential for primary prevention of Alzheimer's disease: an analysis of population-based data

✓ Peer-reviewed alzhub usefulness score 63 out of 100. The Lancet Neurology 2014-07-13

Researchers analyzed population-based data and relative risks from existing meta-analyses to estimate the population-attributable risk of Alzheimer's disease worldwide, in the USA, Europe, and the UK for seven potentially modifiable risk factors.

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment

✓ Peer-reviewed alzhub usefulness score 62 out of 100. JAMA neurology 2021-02-01

The data set included 18 178 patients, of which 10 991 (60.5%) had MCI and 7187 (39.5%) had dementia (mean [SD] age, 75.8 [6.3] years; 9333 women [51.3%]). 3 key findings →

Design: cross-sectional Participants: 18 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus

✓ Peer-reviewed alzhub usefulness score 62 out of 100. JAMA internal medicine 2013-07-01

During the 12-year follow-up period, 61 participants (7.8%) had a reported hypoglycemic event, and 148 (18.9%) developed dementia. 3 key findings →

Participants: 783 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Inequalities in dementia incidence between six racial and ethnic groups over 14 years

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2016-02-11

Dementia rates varied over 60% between groups, providing a comprehensive benchmark for the NAPA goal of reducing disparities. 2 key findings →

Participants: 18,778 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomized / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multicenter collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 32,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 32,180 records, built mostly from automated pulls of Europe PMC (66.5% of the library) and OpenAlex (15.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,045 records (3.2% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events

Last updated